on May 31, 2007
Published online before print May 31, 2007, doi: 10.1161/ATVBAHA.107.142570
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 19, 2007
Accepted on May 16, 2007
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Susanne Zadelaar ;
From the TNO Quality of Life, Gaubius Laboratory, Department of Biosciences, Leiden, The Netherlands.
* To whom correspondence should be addressed. E-mail: teake.kooistra{at}tno.nl.
Abstract--Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E-deficient (ApoE-/-) and LDL receptor-deficient (LDLr-/-) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested.
Key words: mouse models • atherosclerosis • pharmaceutical drugs • statins • ACE inhibitors • AT1 receptor antagonists • PPAR • LXR
This article has been cited by other articles:
 |
|
 |
|
  R. Kleemann, S. Zadelaar, and T. Kooistra Cytokines and atherosclerosis: a comprehensive review of studies in mice Cardiovasc Res, August 1, 2008; 79(3): 360 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Kuo, J. M. Kalbfleisch, P. Rutherford, D. Gifford-Moore, X.-d. Huang, R. Christie, K. Hui, K. Gould, and M. Rekhter Chemical analysis of atherosclerotic plaque cholesterol combined with histology of the same tissue J. Lipid Res., June 1, 2008; 49(6): 1353 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. de Haan, J. de Vries-van der Weij, J. W.A. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M.G. Princen, et al. Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin Circulation, May 13, 2008; 117(19): 2515 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fukuda, M. Sata, N. Ishizaka, and R. Nagai Critical Role of Bone Marrow Angiotensin II Type 1 Receptor in the Pathogenesis of Atherosclerosis in Apolipoprotein E Deficient Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|